Compare LYV & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYV | ONC |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4B | 40.6B |
| IPO Year | 2005 | 2015 |
| Metric | LYV | ONC |
|---|---|---|
| Price | $167.41 | $358.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 28 |
| Target Price | $201.96 | ★ $432.80 |
| AVG Volume (30 Days) | ★ 1.6M | 320.8K |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 140.43 |
| EPS | N/A | ★ 0.31 |
| Revenue | ★ $25,201,406,000.00 | $238,387,000.00 |
| Revenue This Year | $11.57 | $26.33 |
| Revenue Next Year | $9.18 | $14.36 |
| P/E Ratio | ★ N/A | $1,196.77 |
| Revenue Growth | 8.83 | ★ 22179.16 |
| 52 Week Low | $125.34 | $253.95 |
| 52 Week High | $189.25 | $385.22 |
| Indicator | LYV | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 37.03 | 60.26 |
| Support Level | $166.13 | $327.01 |
| Resistance Level | $167.52 | $380.00 |
| Average True Range (ATR) | 3.63 | 6.86 |
| MACD | 0.22 | 0.75 |
| Stochastic Oscillator | 13.57 | 87.88 |
Live Nation is the largest live entertainment company in the world, serving as a concert promoter, venue operator, and ticketing platform. In addition, the firm generates revenue from sponsorships and advertising. With offices in 51 countries, Live Nation promotes concerts globally. It owned, operated, or had exclusive booking rights to more than 400 venues worldwide at the end of 2025, which the firm says makes it the second-largest operator of music venues globally. In 2025, Live Nation promoted nearly 55,000 events, drawing roughly 160 million fans. Ticketmaster is a dominant global ticketing service, selling nearly 650 million tickets in 2025.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.